Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.

Procter & Gamble Pharmaceuticals (P&GP) welcome the new Final Appraisal Determination (FAD) Guidance for the primary and secondary prevention of osteoporosis from NICE.

The revised NICE FAD recommends risedronate - alongside etidronate - as the first alternative treatment option to generic alendronate for postmenopausal women who are unable to comply with the special administration instructions, have a contraindication to, or are intolerant of alendronate (and also meet certain criteria such as BMD T- scores [a measurement of Bone Mineral Density], age and independent risk factors for fracture)i,ii.

(Press release continues - see attached PDF)

This press release was distributed by ResponseSource Press Release Wire on behalf of Health Unlimited (Red Door Communications) in the following categories: Health, Women's Interest & Beauty, Medical & Pharmaceutical, for more information visit